Who is sponsoring NCT02708394?

NCT02708394 is sponsored by Wayne State University.

What drugs are being tested in NCT02708394?

Interventions in NCT02708394: olanzapine, placebo.

Is NCT02708394 still recruiting?

NCT02708394 is currently completed. Last updated 31 October 2023.

Last reviewed 2023-10-31 · How we verify

NCT02708394

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

Completed EARLY_PHASE1 Last updated 31 October 2023

What this trial tests

EARLY_PHASE1 trial testing olanzapine in Adverse Effect of Other Antipsychotics and Neuroleptics in 31 participants. Completed in 1 October 2023.

Timeline

1 February 2017

Primary endpoint
1 October 2023

1 October 2023

Quick facts

Lead sponsor	Wayne State University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	other
Enrollment	31
Start date	1 February 2017
Primary completion	1 October 2023
Estimated completion	1 October 2023
Sites	1 location across United States

Drugs / interventions tested

olanzapine (olanzapine) — full drug profile →
placebo

Conditions studied

Adverse Effect of Other Antipsychotics and Neuroleptics — all drugs for Adverse Effect of Other Antipsychotics and Neuroleptics →
Insulin Resistance — all drugs for Insulin Resistance →

Sponsor

Wayne State University

Who can join

Adults 21 to 45, any sex, with Adverse Effect of Other Antipsychotics and Neuroleptics or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the molecular mechanisms of atypical-antipsychotic induced insulin resistance. This will be accomplished by administering olanzapine or placebo to healthy subjects for 7 days and analyzing genetic and protein changes in peripheral tissues known to play an important role in insulin resistance pathophysiology.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Alterations in Skeletal Muscle Insulin Signaling DNA Methylation: A Pilot Randomized Controlled Trial of Olanzapine in Healthy Volunteers.
Burghardt KJ, Burghardt PR, Howlett BH, Dass SE, et al · · 2024 · cited 3× · PMID 38791018 · DOI 10.3390/biomedicines12051057

Verify or expand the search:

Other trials of olanzapine

Trials testing the same drug.

NCT06850454 — Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy · Phase 3 · recruiting
NCT06600477 — A Study of Olanzapine After Intranasal and Intramuscular Administration · Phase 1 · completed
NCT03557931 — A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schiz · Phase 2 · completed
NCT00149292 — Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo · Phase 2 · completed
NCT00156117 — Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933) · Phase 3 · completed

Other Wayne State University trials

Trials by the same sponsor.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07222306 — Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study · enrolling by invitation
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02708394 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wayne State University
Last refreshed: 31 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02708394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing